---
title: "Vilin Bio Med Ltd (VILINBIO) — Share Price, Financials & Analysis"
symbol: "VILINBIO"
company: "Vilin Bio Med Ltd"
canonical: "https://tapetide.com/stocks/VILINBIO"
isin: "INE0L4V01013"
nse_symbol: "VILINBIO"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 89.9
generated_at: "2026-09-13T19:21:35.691Z"
---

# Vilin Bio Med Ltd (VILINBIO)

Canonical page: https://tapetide.com/stocks/VILINBIO

## Company

- **NSE Symbol:** VILINBIO
- **ISIN:** INE0L4V01013
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2023-06-30
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** vilinbiomed.co.in

## About

Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products[1]

## Latest Price

- **Price:** ₹59
- **Change:** +0.05 (+0.08%)
- **Open:** ₹59
- **Day High:** ₹60.3
- **Day Low:** ₹58.05
- **Previous Close:** ₹58.95
- **Volume:** 32000
- **As Of:** 2026-09-11T09:46:03+00:00

## Key Fundamentals

Observed at 2026-09-11T04:47:04.368518Z.

- **Market Cap:** ₹89.9 Cr
- **Classification:** SME
- **P/E (reported):** 46.8
- **Book Value:** ₹18.6
- **Price to Book:** 3.17
- **Dividend Yield:** 0%
- **ROE:** 0.97%
- **ROCE:** 4.97%
- **Debt to Equity:** 0.01
- **Revenue (yearly):** ₹42.26 Cr
- **Net Income:** ₹1.96 Cr
- **EBITDA:** ₹3.19 Cr
- **52-Week High:** ₹60.95
- **52-Week Low:** ₹18.95
- **RSI (14):** 72.7

## Tapetide Score

- **Score:** 60 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Rising
- **Percentile:** 87.9 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 75.01 | 9% |
| growth | 98.9 | 9% |
| momentum | 98.57 | 12% |
| ownership | 50 | 24% |
| quality | 55.47 | 22% |
| valuation | 35.29 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.

### Weaknesses

- Stock is trading at 3.17 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.92%
- Company has a low return on equity of 3.53% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 102.96% | 113.25% | 122% |
| ebitda margin growth | -84.62% | -8.15% | 6.79% | 10.06% |
| net income growth | -100% | 880% | 16% | 74% |
| revenue growth | -32.65% | 176.21% | 51% | 30% |
| roce | — | 13.73% | -77.14% | 8.99% |
| roe | — | 36.62% | 4.45% | -41.21% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 4.95 | 4.1 | 8.21 | 7.65 | 8.16 | 4.49 | 10.32 | 9.66 | 32.6 |
| Expenses | 4.56 | 2.99 | 6.74 | 6.26 | 8.73 | 4.07 | 9.95 | 9.32 | 29.74 |
| Operating Profit | 0.39 | 1.11 | 1.47 | 1.39 | -0.57 | 0.42 | 0.37 | 0.34 | 2.86 |
| OPM % | 7.88 | 27.07 | 17.9 | 18.17 | -6.99 | 9.35 | 3.59 | 3.52 | 8.77 |
| Other Income | 0 | 0 | 0.02 | 0.11 | 0.22 | 0.22 | 0.25 | 0 | 0 |
| Interest | 0.25 | 0.32 | 0.33 | 0.38 | 0.41 | 0.41 | 0.44 | 0.07 | 0 |
| Depreciation | 0.11 | 0.08 | 0.08 | 0.08 | 0.05 | 0.07 | 0.03 | 0.07 | 0.21 |
| Profit before tax | 0.03 | 0.71 | 1.08 | 1.04 | -0.81 | 0.16 | 0.15 | 0.2 | 2.65 |
| Tax % | 33.33 | 21.13 | 35.19 | 25.96 | -25.93 | 18.75 | 33.33 | 25 | 32.83 |
| Net Profit | 0.02 | 0.55 | 0.69 | 0.77 | -0.61 | 0.12 | 0.1 | 0.15 | 1.78 |
| EPS in Rs | 0.06 | 1.67 | 0.69 | 0.55 | -0.44 | 0.09 | 0.07 | 0.11 | 1.17 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 16.62 | 11.54 | 11.21 | 12.31 | 15.8 | 14.81 | 42.26 |
| Expenses | 15.71 | 10.68 | 10.44 | 9.73 | 14.97 | 14.02 | 39.06 |
| Operating Profit | 0.91 | 0.86 | 0.77 | 2.58 | 0.83 | 0.79 | 3.2 |
| OPM % | 5.48 | 7.45 | 6.87 | 20.96 | 5.25 | 5.33 | 7.57 |
| Other Income | 0.01 | 0 | 0 | 0.02 | 0.32 | 0.47 | 0 |
| Interest | 0.41 | 0.44 | 0.51 | 0.65 | 0.79 | 0.85 | 0.07 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.17 | 0.13 | 0.1 | 0.28 |
| Profit before tax | 0.2 | 0.16 | 0.04 | 1.78 | 0.23 | 0.31 | 2.85 |
| Tax % | 20 | 25 | 25 | 30.34 | 26.09 | 25.81 | 31.93 |
| Net Profit | 0.16 | 0.12 | 0.03 | 1.25 | 0.16 | 0.22 | 1.93 |
| EPS in Rs | 0.48 | 0.36 | 0.09 | 1.26 | 0.11 | 0.16 | 1.27 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 3.3 | 3.3 | 3.3 | 9.95 | 13.95 | 13.95 | 15.25 |
| Reserves | 3.94 | 4.06 | 4.1 | 0.73 | 8.89 | 9.11 | 13.12 |
| Borrowings | 4.53 | 5.52 | 5.3 | 4.93 | 6.83 | 2.57 | 0.21 |
| Other Liabilities | 2.24 | 1.01 | 0.86 | 2.07 | 2.73 | 2.1 | 6.36 |
| Total Liabilities | 14.01 | 13.89 | 13.56 | 17.68 | 32.4 | 27.73 | 34.94 |
| Fixed Assets | 2.13 | 1.87 | 1.65 | 1.51 | 1.38 | 1.28 | 2.87 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1.57 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11.88 | 12.02 | 11.91 | 16.17 | 31.02 | 24.88 | 32.07 |
| Total Assets | 14.01 | 13.89 | 13.56 | 17.68 | 32.4 | 27.73 | 34.94 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -1.46 | -1 | 0.21 | -1.66 | -7.42 | 0.22 | 0.7 |
| Cash from Investing Activity | -0.02 | 0 | 0 | -0.03 | 0.32 | -1.11 | -0.3 |
| Cash from Financing Activity | 1.51 | 0.98 | -0.22 | 1.68 | 8.87 | -5.1 | 1.01 |
| Net Cash Flow | 0.03 | -0.02 | -0.01 | 0 | 1.77 | -5.99 | 1.41 |
| Free Cash Flow | -1.48 | -1 | 0.21 | -1.69 | -7.42 | -1.35 | 0.4 |
| CFO/OP | -156 | -112 | 29 | -43 | -888 | 37 | 49 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 159.66 | 241.96 | 253.64 | 166.04 | 131.22 | 155.51 | 137.85 |
| Inventory Days | 56.13 | 83.17 | 93.82 | 44.74 | 125.41 | 119.5 | 70.03 |
| Days Payable | 49.48 | 33.11 | 26.34 | 60.49 | 54.71 | 37.67 | 32.49 |
| Cash Conversion Cycle | 166.31 | 292.03 | 321.13 | 150.28 | 201.91 | 237.35 | 175.38 |
| Working Capital Days | 110.91 | 204.32 | 211.64 | 45.07 | 76.23 | 195.44 | 168.16 |
| ROCE % | — | 4.87 | 4.3 | 17.17 | 4.51 | 4.2 | 10.77 |

## Shareholding Pattern

### Quarterly

| Category | Jun 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 90.45% | 64.52% | 64.52% | 64.09% | 63.89% | 63.89% | 63.89% | 63.65% | 59.57% | 56.65% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 9.45% | 32.8% | 33.84% | 34.47% | 34.18% | 33.49% | 33.55% | 33.95% | 30.19% | 33.08% |
| Others | 0.1% | 2.68% | 1.65% | 1.45% | 1.94% | 2.62% | 2.57% | 2.39% | 10.24% | 10.27% |
| No. of Shareholders | 827 | 659 | 585 | 581 | 551 | 492 | 476 | 462 | 421 | 382 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 1 / 5

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 54.15 | Buy |
| EMA (10) | 54.64 | Buy |
| SMA (20) | 48.29 | Buy |
| EMA (20) | 50.83 | Buy |
| SMA (50) | 45.79 | Buy |
| EMA (50) | 46.86 | Buy |
| SMA (100) | 43.49 | Buy |
| EMA (100) | 43.23 | Buy |
| SMA (200) | 35.18 | Buy |
| EMA (200) | 37.87 | Buy |

### Oscillators — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 72.76 | Sell |
| MACD (12,26,9) | 4.09 | Buy |
| Stochastic (14,3,3) | 88.16 | Sell |
| ADX (14) | 26.05 | Buy |
| Williams %R (14) | -9.82 | Sell |
| ATR (14) | 2.34 | High Volatility |
| ROC (12) | 36.73 | Buy |
| Stoch RSI (14) | 86.05 | Sell |
| UO (7,14,28) | 73.93 | Sell |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Jul - Filed Regulation 74(5) compliance certificate for quarter ended June 30, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 9 Jul - Filed Regulation 74(5) compliance certificate for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/VILIN2005_09072026130614_Vilin_Certificate_Regulation_74_5_.pdf) |
| 9 April 2026 - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 9 April 2026 - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/VILIN2005_09042026180234_Vilin_Certificate_Regulation_74_5_.pdf) |
| 7 April 2026 - Corporate governance provisions not applicable for quarter ended March 31, 2026 under SME exemption. | [Updates 7 April 2026 - Corporate governance provisions not applicable for quarter ended March 31, 2026 under SME exemption.](https://nsearchives.nseindia.com/corporate/VILIN2005_07042026172836_Vilin_CG.pdf) |
| 6 April 2026 - Promoters and PAC reported no share encumbrance during FY ended March 31, 2026. | [Updates 6 April 2026 - Promoters and PAC reported no share encumbrance during FY ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/VILIN2005_06042026180826_Vilin_Regulation_31_4_.pdf) |
| 4 March 2026 - Allotment of 1,300,000 shares at ₹26 each (₹3.38Cr) on March 4, 2026 to two non-promoters. | [Outcome of Board Meeting 4 March 2026 - Allotment of 1,300,000 shares at ₹26 each (₹3.38Cr) on March 4, 2026 to two non-promoters.](https://nsearchives.nseindia.com/corporate/VILIN2005_04032026115749_Vilin.pdf) |
| 30 May 2026 - Vilin Bio Med confirms it is not a Large Corporate for FY 2026-27 under SEBI circular. | [General Updates 30 May 2026 - Vilin Bio Med confirms it is not a Large Corporate for FY 2026-27 under SEBI circular.](https://nsearchives.nseindia.com/corporate/VILIN2005_30052026142452_Intimation_Large_Corporate.pdf) |
| 30 May 2026 - Document contains only digital signatures and page breaks. | [Outcome of Board Meeting 30 May 2026 - Document contains only digital signatures and page breaks.](https://nsearchives.nseindia.com/corporate/VILIN2005_30052026141027_Vilin_Outcome.pdf) |
| 30 May 2026 - Annual Secretarial Compliance Report not required for FY ended March 31, 2026 under Regulation 15(2). | [General Updates 30 May 2026 - Annual Secretarial Compliance Report not required for FY ended March 31, 2026 under Regulation 15(2).](https://nsearchives.nseindia.com/corporate/VILIN2005_30052026142602_Vilin_ASCR.pdf) |
| 30 March 2026 - NSE granted in-principle listing approval on Mar 30, 2026 for 13,00,000 preferentially allotted shares (FV Rs10). | [General Updates 30 March 2026 - NSE granted in-principle listing approval on Mar 30, 2026 for 13,00,000 preferentially allotted shares (FV Rs10).](https://nsearchives.nseindia.com/corporate/VILIN2005_30032026114956_Vilin_Listing_Approval.pdf) |
| 3 Sep - 20th AGM voting results filed; all 9 resolutions passed on September 2, 2026. | [Shareholders meeting 3 Sep - 20th AGM voting results filed; all 9 resolutions passed on September 2, 2026.](https://nsearchives.nseindia.com/corporate/VILIN2005_03092026163938_VILIN_SR.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30285_VILINBIO_2025_2026_A_1914238_10082026193827.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_27312_VILINBIO_2024_2025_A_06082025195034.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25091_VILINBIO_2023_2024_2308202413110.pdf) |
| from nse | [Annual Report 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_22930_VILINBIO_2022_2023_25082023134236_08252023140000.zip) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:21:35.691Z.